Loading
[225Ac]Ac-ETN029 is an experimental radioligand therapy from Mariana Oncology, in phase 1 trials for small cell lung cancer, large cell neuroendocrine carcinoma of the lung and neuroendocrine prostate cancer and other cancers.
[225Ac]Ac-ETN029 (ETN029, 225Ac-ETN029, 111In-ETN029) is a radioligand therapy (actinium-225) from Mariana Oncology, with Novartis as acquirer. A radioligand therapy against DLL3, a cell-surface protein widely expressed across a range of cancers with limited expression on healthy cells; an indium-111 version is used for imaging. Its furthest stage is phase 1, for small cell lung cancer, large cell neuroendocrine carcinoma of the lung, neuroendocrine prostate cancer and gastroenteropancreatic neuroendocrine carcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07006727 recruiting, sponsored by Novartis Pharmaceuticals. Whether it works in people has not been established unless a trial below reports it.
A radioligand therapy against DLL3, a cell-surface protein widely expressed across a range of cancers with limited expression on healthy cells; an indium-111 version is used for imaging. Connects to DLL3.
1.[225Ac]Ac-ETN029 binds DLL3 on the cancer cell or is taken up by it.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"[225Ac]Ac-ETN029" OR ABSTRACT:"[225Ac]Ac-ETN029" OR TITLE:"ETN029" OR ABSTRACT:"ETN029" OR TITLE:"225Ac-ETN029" OR ABSTRACT:"225Ac-ETN029" OR TITLE:"111In-ETN029" OR ABSTRACT:"111In-ETN029") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about [225Ac]Ac-ETN029, not a curated reading list.
Shares Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Extrapulmonary neuroendocrine carcinoma, DLL3, Neuroendocrine tumours and the tag pipeline.
Shares DLL3, Small-cell lung cancer and the tag pipeline.
Shares DLL3, Small-cell lung cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer, Prostate cancer and the tag pipeline.
Shares Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours and the tag pipeline.
Shares Novartis, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/